prikaz prve stranice dokumenta The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
  Download
PDF 1.84 MB
Scientific paper - Review paper
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
Cardiovascular Diabetology, 18 (2019), 1; https://doi.org/10.1186/s12933-019-0864-7
Fruchart, Jean-Charles; Santos, Raul D.; Aguilar-Salinas, Carlos; Aikawa, Masanori; Al Rasadi, Khalid; Amarenco, Pierre; Barter, Philip J.; Ceska, Richard; Corsini, Alberto; Després, Jean-Pierre; Duriez, Patrick; Eckel, Robert H.; Ezhov, Marat V.; Farnier, Michel; Ginsberg, Henry N.; Hermans, Michel P.; Ishibashi, Shun; Karpe, Fredrik; Kodama, Tatsuhiko; Koenig, Wolfgang; Krempf, Michel; Lim, Soo; Lorenzatti, Alberto J.; McPherson, Ruth; Nuñez-Cortes, Jesus Millan; Nordestgaard, Børge G.; Ogawa, Hisao; Packard, Chris J.; Plutzky, Jorge; Ponte-Negretti, Carlos I.; Pradhan, Aruna; Ray, Kausik K.; Reiner, Željko; Ridker, Paul M.; Ruscica, Massimiliano; Sadikot, Shaukat; Shimano, Hitoshi; Sritara, Piyamitr; Stock, Jane K.; Su, Ta-Chen; Susekov, Andrey V.; Tartar, André; Taskinen, Marja-Riitta; Tenenbaum, Alexander; Tokgözoğlu, Lale S.; Tomlinson, Brian; Tybjærg-Hansen, Anne; Valensi, Paul; Vrablík, Michal; Wahli, Walter; Watts, Gerald F.; Yamashita, Shizuya; Yokote, Koutaro; Zambon, Alberto; Libby, Peter More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Fruchart, J. C., Santos, R. D., Aguilar Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P. ... Libby, P. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 18. (1). doi: 10.1186/s12933-019-0864-7

Fruchart, Jean Charles, et al. "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential." Cardiovascular Diabetology, vol. 18, no. 1, 2019. https://doi.org/10.1186/s12933-019-0864-7

Fruchart, Jean Charles, Raul D. Santos, Carlos Aguilar Salinas, Masanori Aikawa, Khalid Al Rasadi, Pierre Amarenco, Philip J. Barter, et al. "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential." Cardiovascular Diabetology 18, no. 1 (2019). https://doi.org/10.1186/s12933-019-0864-7

Fruchart, J. C., et al. (2019) 'The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential', Cardiovascular Diabetology, 18(1). doi: 10.1186/s12933-019-0864-7

Fruchart JC, Santos RD, Aguilar Salinas C, Aikawa M, Al Rasadi K, Amarenco P, and sur.. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology [Internet]. 2019 June 04 [cited 2024 December 25];18(1). doi: 10.1186/s12933-019-0864-7

J. C. Fruchart, et al., "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential", Cardiovascular Diabetology, vol. 18, no. 1, June 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:859241. [Accessed: 25 December 2024]

Metadata
Title (english)The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
AuthorJean-Charles Fruchart
AuthorRaul D. Santos
AuthorCarlos Aguilar-Salinas
AuthorMasanori Aikawa
AuthorKhalid Al Rasadi
AuthorPierre Amarenco
AuthorPhilip J. Barter
AuthorRichard Ceska
AuthorAlberto Corsini
AuthorJean-Pierre Després
AuthorPatrick Duriez
AuthorRobert H. Eckel
AuthorMarat V. Ezhov
AuthorMichel Farnier
AuthorHenry N. Ginsberg
AuthorMichel P. Hermans
AuthorShun Ishibashi
AuthorFredrik Karpe
AuthorTatsuhiko Kodama
AuthorWolfgang Koenig
AuthorMichel Krempf
AuthorSoo Lim
AuthorAlberto J. Lorenzatti
AuthorRuth McPherson
AuthorJesus Millan Nuñez-Cortes
AuthorBørge G. Nordestgaard
AuthorHisao Ogawa
AuthorChris J. Packard
AuthorJorge Plutzky
AuthorCarlos I. Ponte-Negretti
AuthorAruna Pradhan
AuthorKausik K. Ray
AuthorŽeljko Reiner
AuthorPaul M. Ridker
AuthorMassimiliano Ruscica
AuthorShaukat Sadikot
AuthorHitoshi Shimano
AuthorPiyamitr Sritara
AuthorJane K. Stock
AuthorTa-Chen Su
AuthorAndrey V. Susekov
AuthorAndré Tartar
AuthorMarja-Riitta Taskinen
AuthorAlexander Tenenbaum
AuthorLale S. Tokgözoğlu
AuthorBrian Tomlinson
AuthorAnne Tybjærg-Hansen
AuthorPaul Valensi
AuthorMichal Vrablík
AuthorWalter Wahli
AuthorGerald F. Watts
AuthorShizuya Yamashita
AuthorKoutaro Yokote
AuthorAlberto Zambon
AuthorPeter Libby
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCardiovascular Diabetology
Numberingvol. 18, no. 1
p-ISSN1475-2840
DOIhttps://doi.org/10.1186/s12933-019-0864-7
URN:NBNurn:nbn:hr:105:859241
Publication2019-06-04
Document URLhttp://doi.org/10.1186/s12933-019-0864-7
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:32:27